Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05273749 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
A Phase 3 study, sponsored by Tonix Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 457
- Enrollment target
NCT05273749 is a Phase 3 study that has completed, run by Tonix Pharmaceuticals. The registered enrollment target is 457 participants.
The verdict
NCT05273749, a Phase 3 study, has completed, sponsored by Tonix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 457 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
Interventions
- DRUG Placebo SL Tablet
- DRUG TNX-102 SL Tablet, 5.6 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2022-04-06 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05273749
The ClinicalTrials.gov registry entry for NCT05273749 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo SL Tablet is the first listed.
NCT05273749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05273749 about?
NCT05273749 is a clinical study titled "A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia". This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
What is the current status of trial NCT05273749?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 457 participants. The study started on 2022-04-06. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT05273749?
The interventions under investigation include: Placebo SL Tablet (DRUG), TNX-102 SL Tablet, 5.6 mg (DRUG).
Who is sponsoring clinical trial NCT05273749?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.